A Oliver Sartor


Affiliation: Tulane University
Country: USA


  1. Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt A, Sartor O. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. Oncologist. 2018;: pubmed publisher
    ..KEY POINTS: Biomarkers for anti-PD1 and anti-PDL1 therapy are poorly defined in prostate cancer.Recent advances are defining new important classes of responsive patients. ..
  2. Sartor O, Nakabayashi M, Taplin M, Ross R, Kantoff P, Balk S, et al. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009;7:E90-2 pubmed publisher
    ..9 months (range, 2.7+ to 9.8 months); no patient had a >OR= 50% PSA decline. We conclude that dutasteride added to ketoconazole at the time progression might prolong time to PSA progression in patients with CRPC. ..
  3. Sartor O, Halabi S. Independent data monitoring committees: an update and overview. Urol Oncol. 2015;33:143-8 pubmed publisher
    ..Interim monitoring of safety and efficacy data is an integral part of modern clinical trials. ..
  4. Cotogno P, Ranasinghe L, Ledet E, Lewis B, Sartor O. Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2018;23:791-797 pubmed publisher
    ..Analysis of these simple variables can alert clinicians to those at high risk for prostate cancer that has spread to the liver, a finding of clear importance for clinical management. ..
  5. Egan A, Dong Y, Zhang H, Qi Y, Balk S, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014;40:426-33 pubmed publisher
    ..This has occurred not only within the setting of multiple treatment paradigm changes, but also as a multiplicity of potential molecular mechanisms underlying this disease state have been explored and discovered. ..
  6. Sartor O. Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer. Nat Rev Clin Oncol. 2011;8:515-6 pubmed publisher
    ..The survival gain observed in this pivotal trial is accomplished with few adverse events and conclusively demonstrates that patients with castration levels of serum testosterone remain sensitive to additional hormonal manipulation. ..
  7. Stolten M, Ledet E, Dotiwala A, Luk E, Sartor O. Alternative Digit Ratios and Their Relationship to Prostate Cancer. Clin Genitourin Cancer. 2016;14:149-52 pubmed publisher
    ..The potential relationship between the 2T:2D ratio and age at diagnosis in African-Americans needs additional verification. ..
  8. Steinberger A, Ledet E, Luk E, Cotogno P, Stolten M, Desmond D, et al. Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality. Clin Genitourin Cancer. 2016;14:139-48 pubmed publisher
    ..Additional data are needed in multi-institutional settings to confirm these findings. ..
  9. Sartor O, Lewis B. Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation. Semin Radiat Oncol. 2017;27:87-93 pubmed publisher
    ..Clinical trials with radiation and novel forms of therapy are the key to progress, and newer adaptive clinical trial designs may allow such progress to occur faster. ..

More Information


  1. Manogue C, Ledet E, Guddati A, Lewis B, Sartor O. Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer. Oncologist. 2018;23:383-385 pubmed publisher
    ..We hypothesized that prostate-specific membrane antigen overexpression may result in cancer cells uniquely susceptible to antifolate therapies. ..
  2. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O Sullivan J, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15:738-46 pubmed publisher
    ..We assessed the effect of radium-223 compared with placebo in patients with castration-resistant prostate cancer and bone metastases...
  3. Crawford E, Petrylak D, Sartor O. Navigating the evolving therapeutic landscape in advanced prostate cancer. Urol Oncol. 2017;35S:S1-S13 pubmed publisher
    ..The treatment of advanced prostate cancer and the research related to biomarkers are discussed. ..
  4. Sartor O, Vogelzang N, Sweeney C, Fernandez D, Almeida F, Iagaru A, et al. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018;23:193-202 pubmed publisher
    ..Patients with more advanced disease were less likely to benefit from radium-223. Clinicians should consider baseline clinical characteristics and therapy sequence to provide the greatest clinical value to patients. ..